MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02517398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this Phase I study was to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals. Based on this information, it is hoped to find out which dose could be best for the treatment of patients. There are two parts of this research study: a dose-escalation part and an expansion part. Dose escalation means that the first people taking part in the study will receive low doses of the study drug, and as more people take part, the additional participants will receive a higher dose. This is done to find the safest dose for the study drug. Expansion means that after the dose-escalation part of the study has looked at the safety and effectiveness of different doses, many more people will be invited to take part in the study and will receive the study drug at the safest dose. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.
Study identification
- NCT ID
- NCT02517398
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2015 (Actual)
- Primary completion
- May 23, 2022 (Actual)
- Completion
- May 23, 2022 (Actual)
- Last update posted
- May 3, 2024
2015 – 2022
United States locations
- U.S. sites
- 36
- U.S. states
- 21
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Clinical Research Center | Tucson | Arizona | 85715 | — |
| Pacific Oncology Associates | Escondido | California | 92025 | — |
| University of California Davis Health System | Sacramento | California | 95817 | — |
| California Pacific Medical Center | San Francisco | California | 94118 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Rocky Mountain Cancer Centers, LLP | Denver | Colorado | 80218 | — |
| Eastern Connecticut Hematology/Oncology Assoc. | Norwich | Connecticut | 06360 | — |
| Sylvester Cancer Center | Miami | Florida | 33136 | — |
| Hematology - Oncology Associates of Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| University Cancer & Blood Center, LLC | Athens | Georgia | 30607 | — |
| Southeastern Regional Medical Center | Newnan | Georgia | 30265 | — |
| Metairie Oncologists, LLC | Metairie | Louisiana | 70006 | — |
| National Cancer Institute | Bethesda | Maryland | 20892 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Michigan State University | Lansing | Michigan | 48910 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| UC Health Clinical Trials Office | Cincinnati | Ohio | 45206 | — |
| Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
| Penn State University Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Greenville Hospital System University Medical Center (ITOR) | Greenville | South Carolina | 29605 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| Texas Oncology, P.A. - Austin | Austin | Texas | 78705 | — |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 75230 | — |
| Texas Oncology, P.A. - Fort Worth | Fort Worth | Texas | 76104 | — |
| Oncology Consultants, P.A. | Houston | Texas | 77030 | — |
| University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | 78229 | — |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates - Hampton | Norfolk | Virginia | 23502 | — |
| Compass Oncology | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02517398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2024 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02517398 live on ClinicalTrials.gov.